Pfizer, Inc. · NYSE:PFE
Pfizer — Q3 2015 Earnings Presentation
15 slides from Pfizer's earnings presentation, Oct 27, 2015
Slide 1: Third Quarter 2015 Earnings Teleconference
Third Quarter 2015 Earnings Teleconference October 27, 2015
Slide 2: Introduction
Introduction Chuck Triano Senior Vice President, Investor Relations Third Quarter 2015 Earnings
Slide 3: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information l Our discussions during this conference call will include forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candid
Slide 4: Opening Remarks
Opening Remarks Ian Read Chairman and Chief Executive Officer Third Quarter 2015 Earnings
Slide 5: CEO Perspectives
CEO Perspectives l Achieved another quarter of strong operational performance, driven by: Ü Strong performance of certain in-line brands, including Lyrica in the U.S., Chantix and Enbrel Ü Uptake from our new products, including Prevnar 13 in adults, Ibrance and Eliquis Ü Growth in emerging markets
Slide 6: Financial Review
Financial Review Frank D’Amelio Executive Vice President & Chief Financial Officer Third Quarter 2015 Earnings
Slide 7: Income Statement Highlights
Income Statement Highlights ($ Millions, Except Per Share Amounts and Percentages) Third Quarter 2015 2014 Change Reported Revenues(1) $12,087 $12,361 (2%) Adjusted Income(2) 3,728 3,655 2% Adjusted Diluted EPS(2) 0.60 0.57 5% Reported Net Income(1) 2,130 2,666 (20%) Reported Diluted EPS(1) 0.34 0.4
Slide 8: Impact of Foreign Exchange on Revenues and Select Adjusted Income Components
Impact of Foreign Exchange on Revenues(1) and Select Adjusted Income(1) Components ($ Millions, Except Percentages) Favorable / (Unfavorable) Third Quarter 2015 2014 FX Impact Reported Revenues(1) $12,087 $12,361 ($1,069) » (9%) Cost of Sales(1) 2,108 2,244 343 » 15% SI&A Expenses(1) 3,276 3,299 223
Slide 9: Global Innovative Pharmaceutical (GIP) Selected Financial Highlights
Global Innovative Pharmaceutical (GIP) Selected Financial Highlights ($ Millions, Except Percentages) l Q3 2015 revenues increased 10% operationally to Third Quarter $3,521M vs. Q3 2014 % Change Ü Driven primarily by operational growth of Eliquis 2015 2014 Total Oper. globally, Lyrica primarily in t
Slide 10: Global Vaccines, Oncology and Consumer Healthcare (VOC) Selected Financial Highlights
Global Vaccines, Oncology and Consumer Healthcare (VOC) Selected Financial Highlights ($ Millions, Except Percentages) Third Quarter l Q3 2015 revenues increased 37% operationally to $3,231M vs. Q3 2014 % Change 2015 2014 Ü Primarily driven by continued strong uptake of Total Oper. Prevnar 13 among
Slide 11: Global Established Pharmaceutical (GEP) Selected Financial Highlights
Global Established Pharmaceutical (GEP) Selected Financial Highlights ($ Millions, Except Percentages) Third Quarter l Q3 2015 revenues declined 8% operationally to $5,219M vs. Q3 2014 % Change Ü LOEs negatively impacted revenues by $0.9B, or 2015 2014 Total Oper. 14%, operationally; Revenue from al
Slide 12: 2015 Financial Guidance
(1)(2) 2015 Financial Guidance $47.5 to $48.5 billion Reported Revenues(3) (previously $46.5 to $47.5 billion) 18.7% to 19.2% Adjusted Cost of Sales(3) as a % of Reported Revenues(3) (previously 18.0% to 18.5%) $13.6 to $14.1 billion Adjusted SI&A Expenses(3) (previously $12.8 to $13.8 billion) $7.5
Slide 13: Reconciliation of Certain Components of 2015 Financial Guidance
Reconciliation of Certain Components of 2015 Financial Guidance(2) from July 28, 2015 to October 27, 2015 Reported Reported Diluted Adjusted Diluted Revenues(1) EPS(1) EPS(1) $45.0 to $46.0 2015 Financial Guidance Provided on July 28, 2015 $1.38 to $1.47 $2.01 to $2.07 billion Guidance Update Provid
Slide 14: Key Takeaways
Key Takeaways Achieved strong Q3 2015 financial performance, with our fourth consecutive quarter of Pfizer standalone operational revenue growth, primarily driven by: Ü Strength of Prevnar 13 in adults, Ibrance, and Eliquis, all of which are early in their life cycles Raised the midpoint of our 2015
Slide 15: Q&A Session
Third Quarter 2015 Earnings Teleconference Q&A Session October 27, 2015